Uridine Triacetate is now legally available in the US. This drug converts to Triacetyluridine, which has more than 30 years of clinical experience, and clinically proven to prevent neurological damage in Huntington's patients, and also clinically proven to treat and reverse mytochondrial toxicity.
The drug was first used as a bailout for cancer patients who used Fluororacil and for patients with bipolar condition. Its current FDA approval is for Fluororacil, but the drug has a wide range of applications where neuro protection is required.
The drug is currently available through a compassionate use program from a company called Wellstat Therapeutics.
The drug was first used as a bailout for cancer patients who used Fluororacil and for patients with bipolar condition. Its current FDA approval is for Fluororacil, but the drug has a wide range of applications where neuro protection is required.
The drug is currently available through a compassionate use program from a company called Wellstat Therapeutics.